Drug intelligence / Profile preview

linoleic acid + ceramide + mometasone furoate

Development stage: Unknown
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

A combination therapy consisting of a linoleic acid-ceramide (LA-Cer) containing moisturizer used together with mometasone furoate (a topical corticosteroid). This combination helps repair the skin barrier function while reducing inflammation and pruritus in various dermatological conditions. Clinical studies have shown that this combination enhances therapeutic effects compared to mometasone furoate alone, with lower relapse rates and improved skin barrier parameters.

Targets

GR (Glucocorticoid receptor)Stratum corneum lipid matrix

Beyond the preview

Go deeper on linoleic acid + ceramide + mometasone furoate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on linoleic acid + ceramide + mometasone furoate.

Explore the full profile